查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
粪便钙蛋白检测市场（患者类型：成人和儿科；检测类型：ELISA、酶联免疫法和定量免疫层析法） - 2023-2031年全球行业分析、规模、份额、增长、趋势和预测
市场调查报告书
商品编码
1301433

粪便钙蛋白检测市场（患者类型：成人和儿科；检测类型：ELISA、酶联免疫法和定量免疫层析法） - 2023-2031年全球行业分析、规模、份额、增长、趋势和预测

Fecal Calprotectin Test Market (Patient Type: Adult and Pediatric; Assay Type: ELISA, Enzyme Fluoroimmunoassay, and Quantitative Immune-chromatography) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 203 Pages | 商品交期: 2-10个工作天内

价格

粪便钙蛋白检测仪市场 - 报告范围

TMR关于全球粪便钙蛋白检测市场的报告研究了过去以及当前的增长趋势和机会，以获得对2023年至2031年预测期间市场指标的宝贵见解。报告提供了2017-2031年期间全球粪便钙蛋白检测市场的收入，考虑到2023年为基准年，2031年为预测年。报告还提供了2023年至2031年全球粪便钙蛋白检测市场的复合年增长率（CAGR %）。

该报告是在广泛研究后编写的。一级研究涉及大部分的研究工作，其中分析师与关键意见领袖、行业领袖和意见制造者进行了访谈。二级研究包括参考主要参与者的产品文献、年度报告、新闻稿和相关文件，以了解粪便钙蛋白检测市场。

该报告深入研究了全球粪便钙蛋白检测市场的竞争格局。已经确定了在全球粪便钙蛋白检测市场运作的主要参与者，并对其中每一个参与者的各种属性进行了分析。公司概况、财务状况、近期发展和SWOT是本报告中介绍的全球粪便钙蛋白检测市场参与者的属性。

目录

第一章：前言

  • 市场定义和范围
  • 市场细分
  • 主要研究目标
  • 研究重点

第二章：假设和研究方法

第三章：执行摘要：全球市场

第四章：市场概述

  • 简介
    • 病人类型的定义
    • 行业演变/发展
  • 概述
  • 市场动态
    • 驱动力
    • 限制因素
    • 机会
  • 2017-2031年全球市场分析和预测
    • 市场收入预测

第5章：关键洞察力

  • 技术进步
  • 疾病流行病学
  • 监管情况
  • 价格分析
  • COVID-19影响分析

第六章：全球市场分析与预测：按病人类型分类

  • 介绍和定义
  • 主要研究结果/发展情况
  • 市场价值预测：按病人类型，2017-2031年
    • 成人
    • 儿科
  • 市场吸引力分析：按病人类型

第7章 ：全球市场分析与预测：按检测类型分类

  • 介绍和定义
  • 主要研究结果/发展情况
  • 市场价值预测：按检测类型，2017-2031年
    • ELISA（酶联免疫吸附法）
    • 酶联免疫分析法（Enzyme Fluoroimmunoassay
    • 定量免疫层析法
  • 市场吸引力分析：按检测类型

第八章：全球市场分析与预测：按适应症分类

  • 介绍和定义
  • 主要研究结果/发展情况
  • 市场价值预测：按适应症分类，2017-2031年
    • 炎症性肠病
    • 结直肠癌
    • 乳糜泻
  • 市场吸引力分析：按适应症分类

第九章：全球市场分析与预测：按终端用户分类

  • 介绍和定义
  • 主要研究结果/发展情况
  • 市场价值预测：按终端用户，2017-2031年
    • 医院
    • 诊断实验室
    • 学术和研究机构
  • 市场吸引力分析：按终端用户分类

第十章：全球市场分析与预测：按地区划分

  • 主要发现
  • 市场价值预测：按地区
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力分析：按地区

第11章 ：北美洲市场分析与预测

  • 简介
    • 主要研究结果
  • 市场价值预测：按病人类型，2017-2031年
    • 成人
    • 儿科
  • 市场价值预测：按检测类型，2017-2031年
    • ELISA（酶联免疫吸附法）
    • 酶联免疫分析法（Enzyme Fluoroimmunoassay
    • 定量免疫层析法
  • 市场价值预测：按适应症分类，2017-2031年
    • 炎症性肠病
    • 结直肠癌
    • 腹腔疾病
  • 市场价值预测：按终端用户，2017-2031年
    • 医院
    • 诊断实验室
    • 学术和研究机构
  • 市场价值预测：按国家划分，2017-2031年
    • 美国
    • 加拿大
  • 市场吸引力分析
    • 按病人类型
    • 按化验类型
    • 按适应症分类
    • 按终端用户分类
    • 按国家分类

第12章 ：欧洲市场分析和预测

  • 简介
    • 主要发现
  • 市场价值预测：按病人类型，2017-2031年
    • 成人
    • 儿科
  • 市场价值预测：按检测类型，2017-2031年
    • ELISA（酶联免疫吸附法）
    • 酶联免疫分析法（Enzyme Fluoroimmunoassay
    • 定量免疫层析法
  • 市场价值预测：按适应症分类，2017-2031年
    • 炎症性肠病
    • 结直肠癌
    • 腹腔疾病
  • 市场价值预测：按终端用户，2017-2031年
    • 医院
    • 诊断实验室
    • 学术和研究机构
  • 市场价值预测：按国家/次区域，2017-2031年
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 欧洲其他地区
  • 市场吸引力分析
    • 按病人类型
    • 按检测类型
    • 按适应症分类
    • 按终端用户
    • 按国家/次区域分类

第13章 ：亚太地区市场分析和预测

  • 简介
    • 主要发现
  • 市场价值预测：按病人类型，2017-2031年
    • 成人
    • 儿科
  • 市场价值预测：按检测类型，2017-2031年
    • ELISA（酶联免疫吸附法）
    • 酶联免疫分析法（Enzyme Fluoroimmunoassay
    • 定量免疫层析法
  • 市场价值预测：按适应症分类，2017-2031年
    • 炎症性肠病
    • 结直肠癌
    • 腹腔疾病
  • 市场价值预测：按终端用户，2017-2031年
    • 医院
    • 诊断实验室
    • 学术和研究机构
  • 市场价值预测：按国家/次区域，2017-2031年
    • 中国
    • 日本
    • 印度
    • 澳大利亚和新西兰
    • 亚太其他地区
  • 市场吸引力分析
    • 按病人类型
    • 按检测类型
    • 按适应症分类
    • 按终端用户
    • 按国家/次区域分类

第十四章 ：拉美市场分析和预测

  • 简介
    • 主要发现
  • 市场价值预测：按病人类型，2017-2031年
    • 成人
    • 儿科
  • 市场价值预测：按检测类型，2017-2031年
    • ELISA（酶联免疫吸附法）
    • 酶联免疫分析法（Enzyme Fluoroimmunoassay
    • 定量免疫层析法
  • 市场价值预测：按适应症分类，2017-2031年
    • 炎症性肠病
    • 结直肠癌
    • 腹腔疾病
  • 市场价值预测：按终端用户，2017-2031年
    • 医院
    • 诊断实验室
    • 学术和研究机构
  • 市场价值预测：按国家/次区域，2017-2031年
    • 巴西
    • 墨西哥
    • 拉美其他地区
  • 市场吸引力分析
    • 按病人类型
    • 按检测类型
    • 按适应症分类
    • 按终端用户
    • 按国家/次区域分类

第15章 ：中东和非洲市场分析和预测

  • 简介
    • 主要发现
  • 市场价值预测：按病人类型，2017-2031年
    • 成人
    • 儿科
  • 市场价值预测：按检测类型，2017-2031年
    • ELISA（酶联免疫吸附法）
    • 酶联免疫分析法（Enzyme Fluoroimmunoassay
    • 定量免疫层析法
  • 市场价值预测：按适应症分类，2017-2031年
    • 炎症性肠病
    • 结直肠癌
    • 腹腔疾病
  • 市场价值预测：按终端用户，2017-2031年
    • 医院
    • 诊断实验室
    • 学术和研究机构
  • 市场价值预测：按国家/次区域，2017-2031年
    • 海湾合作委员会国家
    • 南非
    • 中东和非洲其他地区
  • 市场吸引力分析
    • 按病人类型
    • 按化验类型
    • 按适应症分类
    • 按终端用户
    • 按国家/次区域分类

第16章 ：竞争格局

  • 市场参与者 - 竞争矩阵（按公司层级和规模）。
  • 市场份额分析：按公司分类 (2022)
  • 公司简介
    • Abbexa
    • ALPCO
    • Alpha Laboratories
    • Biomerica
    • BUHLMANN Laboratories AG
    • DRG Instruments GmbH
    • EagleBio
    • Epitope Diagnostics, Inc.
    • OPERON, S.A.
    • R-Biopharm AG
    • Svar Life Science
    • Thermo Fisher Scientific, Inc.
    • Werfen
    • SENTINEL CH. SpA
    • Diazyme Laboratories, Inc.
    • DiAgam
Product Code: TMRGL78383

Fecal Calprotectin Test Market - Scope of Report

TMR's report on the global Fecal Calprotectin Test market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Fecal Calprotectin Test market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Fecal Calprotectin Test market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Fecal Calprotectin Test market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Fecal Calprotectin Test market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Fecal Calprotectin Test market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Fecal Calprotectin Test market.

The report delves into the competitive landscape of the global Fecal Calprotectin Test market. Key players operating in the global Fecal Calprotectin Test market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Fecal Calprotectin Test market profiled in this report.

Key Questions Answered in Global Fecal Calprotectin Test Market Report:

  • What is the sales/revenue generated by Fecal Calprotectin Test across all regions during the forecast period?
  • What are the opportunities in the global Fecal Calprotectin Test market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Fecal Calprotectin Test Market - Research Objectives and Research Approach

The comprehensive report on the global Fecal Calprotectin Test market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Fecal Calprotectin Test market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Fecal Calprotectin Test market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Fecal Calprotectin Test Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Patient Type Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Fecal Calprotectin Test Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Technological Advancement
  • 5.2. Diseases Epidemiology
  • 5.3. Regulatory Scenario
  • 5.4. Pricing Analysis
  • 5.5. COVID-19 Impact Analysis

6. Global Fecal Calprotectin Test Market Analysis and Forecast, by Patient Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Patient Type, 2017-2031
    • 6.3.1. Adult
    • 6.3.2. Pediatric
  • 6.4. Market Attractiveness Analysis, by Patient Type

7. Global Fecal Calprotectin Test Market Analysis and Forecast, by Assay Type

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Assay Type, 2017-2031
    • 7.3.1. ELISA (Enzyme linked Immunosorbent Assay)
    • 7.3.2. Enzyme Fluoroimmunoassay
    • 7.3.3. Quantitative Immune-chromatography
  • 7.4. Market Attractiveness Analysis, by Assay Type

8. Global Fecal Calprotectin Test Market Analysis and Forecast, by Indication

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast, by Indication, 2017-2031
    • 8.3.1. Inflammatory Bowel Disease
    • 8.3.2. Colorectal Cancer
    • 8.3.3. Celiac Disease
  • 8.4. Market Attractiveness Analysis, by Indication

9. Global Fecal Calprotectin Test Market Analysis and Forecast, by End-user

  • 9.1. Introduction & Definition
  • 9.2. Key Findings / Developments
  • 9.3. Market Value Forecast, by End-user, 2017-2031
    • 9.3.1. Hospitals
    • 9.3.2. Diagnostic Laboratories
    • 9.3.3. Academic & Research Institutes
  • 9.4. Market Attractiveness Analysis, by End-user

10. Global Fecal Calprotectin Test Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness Analysis, by Region

11. North America Fecal Calprotectin Test Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Patient Type, 2017-2031
    • 11.2.1. Adult
    • 11.2.2. Pediatric
  • 11.3. Market Value Forecast, by Assay Type, 2017-2031
    • 11.3.1. ELISA (Enzyme linked Immunosorbent Assay)
    • 11.3.2. Enzyme Fluoroimmunoassay
    • 11.3.3. Quantitative Immune-chromatography
  • 11.4. Market Value Forecast, by Indication, 2017-2031
    • 11.4.1. Inflammatory Bowel Disease
    • 11.4.2. Colorectal Cancer
    • 11.4.3. Celiac Disease
  • 11.5. Market Value Forecast, by End-user, 2017-2031
    • 11.5.1. Hospitals
    • 11.5.2. Diagnostic Laboratories
    • 11.5.3. Academic & Research Institutes
  • 11.6. Market Value Forecast, by Country, 2017-2031
    • 11.6.1. U.S.
    • 11.6.2. Canada
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Patient Type
    • 11.7.2. By Assay Type
    • 11.7.3. By Indication
    • 11.7.4. By End-user
    • 11.7.5. By Country

12. Europe Fecal Calprotectin Test Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Patient Type, 2017-2031
    • 12.2.1. Adult
    • 12.2.2. Pediatric
  • 12.3. Market Value Forecast, by Assay Type, 2017-2031
    • 12.3.1. ELISA (Enzyme linked Immunosorbent Assay)
    • 12.3.2. Enzyme Fluoroimmunoassay
    • 12.3.3. Quantitative Immune-chromatography
  • 12.4. Market Value Forecast, by Indication, 2017-2031
    • 12.4.1. Inflammatory Bowel Disease
    • 12.4.2. Colorectal Cancer
    • 12.4.3. Celiac Disease
  • 12.5. Market Value Forecast, by End-user, 2017-2031
    • 12.5.1. Hospitals
    • 12.5.2. Diagnostic Laboratories
    • 12.5.3. Academic & Research Institutes
  • 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.6.1. Germany
    • 12.6.2. U.K.
    • 12.6.3. France
    • 12.6.4. Italy
    • 12.6.5. Spain
    • 12.6.6. Rest of Europe
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Patient Type
    • 12.7.2. By Assay Type
    • 12.7.3. By Indication
    • 12.7.4. By End-user
    • 12.7.5. By Country/Sub-region

13. Asia Pacific Fecal Calprotectin Test Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Patient Type, 2017-2031
    • 13.2.1. Adult
    • 13.2.2. Pediatric
  • 13.3. Market Value Forecast, by Assay Type, 2017-2031
    • 13.3.1. ELISA (Enzyme linked Immunosorbent Assay)
    • 13.3.2. Enzyme Fluoroimmunoassay
    • 13.3.3. Quantitative Immune-chromatography
  • 13.4. Market Value Forecast, by Indication, 2017-2031
    • 13.4.1. Inflammatory Bowel Disease
    • 13.4.2. Colorectal Cancer
    • 13.4.3. Celiac Disease
  • 13.5. Market Value Forecast, by End-user, 2017-2031
    • 13.5.1. Hospitals
    • 13.5.2. Diagnostic Laboratories
    • 13.5.3. Academic & Research Institutes
  • 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.6.1. China
    • 13.6.2. Japan
    • 13.6.3. India
    • 13.6.4. Australia & New Zealand
    • 13.6.5. Rest of Asia Pacific
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Patient Type
    • 13.7.2. By Assay Type
    • 13.7.3. By Indication
    • 13.7.4. By End-user
    • 13.7.5. By Country/Sub-region

14. Latin America Fecal Calprotectin Test Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Patient Type, 2017-2031
    • 14.2.1. Adult
    • 14.2.2. Pediatric
  • 14.3. Market Value Forecast, by Assay Type, 2017-2031
    • 14.3.1. ELISA (Enzyme linked Immunosorbent Assay)
    • 14.3.2. Enzyme Fluoroimmunoassay
    • 14.3.3. Quantitative Immune-chromatography
  • 14.4. Market Value Forecast, by Indication, 2017-2031
    • 14.4.1. Inflammatory Bowel Disease
    • 14.4.2. Colorectal Cancer
    • 14.4.3. Celiac Disease
  • 14.5. Market Value Forecast, by End-user, 2017-2031
    • 14.5.1. Hospitals
    • 14.5.2. Diagnostic Laboratories
    • 14.5.3. Academic & Research Institutes
  • 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.6.1. Brazil
    • 14.6.2. Mexico
    • 14.6.3. Rest of Latin America
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Patient Type
    • 14.7.2. By Assay Type
    • 14.7.3. By Indication
    • 14.7.4. By End-user
    • 14.7.5. By Country/Sub-region

15. Middle East & Africa Fecal Calprotectin Test Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Patient Type, 2017-2031
    • 15.2.1. Adult
    • 15.2.2. Pediatric
  • 15.3. Market Value Forecast, by Assay Type, 2017-2031
    • 15.3.1. ELISA (Enzyme linked Immunosorbent Assay)
    • 15.3.2. Enzyme Fluoroimmunoassay
    • 15.3.3. Quantitative Immune-chromatography
  • 15.4. Market Value Forecast, by Indication, 2017-2031
    • 15.4.1. Inflammatory Bowel Disease
    • 15.4.2. Colorectal Cancer
    • 15.4.3. Celiac Disease
  • 15.5. Market Value Forecast, by End-user, 2017-2031
    • 15.5.1. Hospitals
    • 15.5.2. Diagnostic Laboratories
    • 15.5.3. Academic & Research Institutes
  • 15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 15.6.1. GCC Countries
    • 15.6.2. South Africa
    • 15.6.3. Rest of Middle East & Africa
  • 15.7. Market Attractiveness Analysis
    • 15.7.1. By Patient Type
    • 15.7.2. By Assay Type
    • 15.7.3. By Indication
    • 15.7.4. By End-user
    • 15.7.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competitive Matrix (by tier and size of companies)
  • 16.2. Market Share Analysis, by Company (2022)
  • 16.3. Company Profiles
    • 16.3.1. Abbexa
      • 16.3.1.1. Company Overview
      • 16.3.1.2. Drug Class Portfolio
      • 16.3.1.3. SWOT Analysis
      • 16.3.1.4. Financial Overview
      • 16.3.1.5. Strategic Overview
    • 16.3.2. ALPCO
      • 16.3.2.1. Company Overview
      • 16.3.2.2. Drug Class Portfolio
      • 16.3.2.3. SWOT Analysis
      • 16.3.2.4. Financial Overview
      • 16.3.2.5. Strategic Overview
    • 16.3.3. Alpha Laboratories
      • 16.3.3.1. Company Overview
      • 16.3.3.2. Drug Class Portfolio
      • 16.3.3.3. SWOT Analysis
      • 16.3.3.4. Financial Overview
      • 16.3.3.5. Strategic Overview
    • 16.3.4. Biomerica
      • 16.3.4.1. Company Overview
      • 16.3.4.2. Drug Class Portfolio
      • 16.3.4.3. SWOT Analysis
      • 16.3.4.4. Financial Overview
      • 16.3.4.5. Strategic Overview
    • 16.3.5. BUHLMANN Laboratories AG
      • 16.3.5.1. Company Overview
      • 16.3.5.2. Drug Class Portfolio
      • 16.3.5.3. SWOT Analysis
      • 16.3.5.4. Financial Overview
      • 16.3.5.5. Strategic Overview
    • 16.3.6. DRG Instruments GmbH
      • 16.3.6.1. Company Overview
      • 16.3.6.2. Drug Class Portfolio
      • 16.3.6.3. SWOT Analysis
      • 16.3.6.4. Financial Overview
      • 16.3.6.5. Strategic Overview
    • 16.3.7. EagleBio
      • 16.3.7.1. Company Overview
      • 16.3.7.2. Drug Class Portfolio
      • 16.3.7.3. SWOT Analysis
      • 16.3.7.4. Financial Overview
      • 16.3.7.5. Strategic Overview
    • 16.3.8. Epitope Diagnostics, Inc.
      • 16.3.8.1. Company Overview
      • 16.3.8.2. Drug Class Portfolio
      • 16.3.8.3. SWOT Analysis
      • 16.3.8.4. Financial Overview
      • 16.3.8.5. Strategic Overview
    • 16.3.9. OPERON, S.A.
      • 16.3.9.1. Company Overview
      • 16.3.9.2. Drug Class Portfolio
      • 16.3.9.3. SWOT Analysis
      • 16.3.9.4. Financial Overview
      • 16.3.9.5. Strategic Overview
    • 16.3.10. R-Biopharm AG
      • 16.3.10.1. Company Overview
      • 16.3.10.2. Drug Class Portfolio
      • 16.3.10.3. SWOT Analysis
      • 16.3.10.4. Financial Overview
      • 16.3.10.5. Strategic Overview
    • 16.3.11. Svar Life Science
      • 16.3.11.1. Company Overview
      • 16.3.11.2. Drug Class Portfolio
      • 16.3.11.3. SWOT Analysis
      • 16.3.11.4. Financial Overview
      • 16.3.11.5. Strategic Overview
    • 16.3.12. Thermo Fisher Scientific, Inc.
      • 16.3.12.1. Company Overview
      • 16.3.12.2. Drug Class Portfolio
      • 16.3.12.3. SWOT Analysis
      • 16.3.12.4. Financial Overview
      • 16.3.12.5. Strategic Overview
    • 16.3.13. Werfen
      • 16.3.13.1. Company Overview
      • 16.3.13.2. Drug Class Portfolio
      • 16.3.13.3. SWOT Analysis
      • 16.3.13.4. Financial Overview
      • 16.3.13.5. Strategic Overview
    • 16.3.14. SENTINEL CH. SpA
      • 16.3.14.1. Company Overview
      • 16.3.14.2. Drug Class Portfolio
      • 16.3.14.3. SWOT Analysis
      • 16.3.14.4. Financial Overview
      • 16.3.14.5. Strategic Overview
    • 16.3.15. Diazyme Laboratories, Inc.
      • 16.3.15.1. Company Overview
      • 16.3.15.2. Drug Class Portfolio
      • 16.3.15.3. SWOT Analysis
      • 16.3.15.4. Financial Overview
      • 16.3.15.5. Strategic Overview
    • 16.3.16. DiAgam
      • 16.3.16.1. Company Overview
      • 16.3.16.2. Drug Class Portfolio
      • 16.3.16.3. SWOT Analysis
      • 16.3.16.4. Financial Overview
      • 16.3.16.5. Strategic Overview

List of Tables

  • Table 01: Global Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Patient Type, 2017-2031
  • Table 02: Global Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031
  • Table 03: Global Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 04: Global Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 05: Global Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 06: North America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 07: North America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Patient Type, 2017-2031
  • Table 08: North America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031
  • Table 09: North America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 10: North America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 11: Europe Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 12: Europe Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Patient Type, 2017-2031
  • Table 13: Europe Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031
  • Table 14: Europe Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 15: Europe Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 16: Asia Pacific Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 17: Asia Pacific Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Patient Type, 2017-2031
  • Table 18: Asia Pacific Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031
  • Table 19: Asia Pacific Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 20: Asia Pacific Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 21: Latin America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Latin America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Patient Type, 2017-2031
  • Table 23: Latin America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031
  • Table 24: Latin America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 25: Latin America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 26: Middle East & Africa Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 27: Middle East & Africa Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Product Type, 2017-2031
  • Table 28: Middle East & Africa Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031
  • Table 29: Middle East & Africa Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031
  • Table 30: Middle East & Africa Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031

List of Figures

  • Figure 01: Global Fecal Calprotectin Test Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Fecal Calprotectin Test Market Value Share, by Patient Type, 2022
  • Figure 03: Global Fecal Calprotectin Test Market Value Share, by Assay Type, 2022
  • Figure 04: Global Fecal Calprotectin Test Market Value Share, by Indication, 2022
  • Figure 05: Global Fecal Calprotectin Test Market Value Share, by End-user, 2022
  • Figure 06: Global Fecal Calprotectin Test Market Value Share, by Region, 2022
  • Figure 07: Global Fecal Calprotectin Test Market Value Share Analysis, by Patient Type, 2022 and 2031
  • Figure 08: Global Fecal Calprotectin Test Market (US$ Mn), by Adult, 2017-2031
  • Figure 09 Global Fecal Calprotectin Test Market (US$ Mn), by Pediatric, 2017-2031
  • Figure 10: Global Fecal Calprotectin Test Market Attractiveness Analysis, by Patient Type, 2023-2031
  • Figure 11: Global Fecal Calprotectin Test Market Value Share Analysis, by Assay Type, 2022 and 2031
  • Figure 12: Global Fecal Calprotectin Test Market (US$ Mn), by ELISA (Enzyme linked Immunosorbent Assay), 2017-2031
  • Figure 13 Global Fecal Calprotectin Test Market (US$ Mn), by Enzyme Fluoroimmunoassay, 2017-2031
  • Figure 14: Global Fecal Calprotectin Test Market (US$ Mn), by Quantitative Immune-chromatography, 2017-2031
  • Figure 15: Global Fecal Calprotectin Test Market Attractiveness Analysis, by Assay Type, 2023-2031
  • Figure 16: Global Fecal Calprotectin Test Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 17: Global Fecal Calprotectin Test Market (US$ Mn), by Inflammatory Bowel Disease, 2017-2031
  • Figure 18: Global Fecal Calprotectin Test Market (US$ Mn), by Colorectal Cancer, 2017-2031
  • Figure 19: Global Fecal Calprotectin Test Market (US$ Mn), by Celiac Disease, 2017-2031
  • Figure 20: Global Fecal Calprotectin Test Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 21: Global Fecal Calprotectin Test Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 22: Global Fecal Calprotectin Test Market (US$ Mn), by Hospitals, 2017-2031
  • Figure 23: Global Fecal Calprotectin Test Market (US$ Mn), by Diagnostic Laboratories, 2017-2031
  • Figure 24: Global Fecal Calprotectin Test Market (US$ Mn), by Academic & Research Institutes, 2017-2031
  • Figure 25: Global Fecal Calprotectin Test Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 26: Global Fecal Calprotectin Test Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 27: Global Fecal Calprotectin Test Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 28: North America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 29: North America Fecal Calprotectin Test Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 30: North America Fecal Calprotectin Test Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 31: North America Fecal Calprotectin Test Market Value Share Analysis, by Patient Type, 2022 and 2031
  • Figure 32: North America Fecal Calprotectin Test Market Attractiveness Analysis, by Patient Type, 2023-2031
  • Figure 33: North America Fecal Calprotectin Test Market Value Share Analysis, by Assay Type, 2022 and 2031
  • Figure 34: North America Fecal Calprotectin Test Market Attractiveness Analysis, by Assay Type, 2023-2031
  • Figure 35: North America Fecal Calprotectin Test Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 36: North America Fecal Calprotectin Test Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 37: North America Fecal Calprotectin Test Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 38: North America Fecal Calprotectin Test Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 39: Europe Fecal Calprotectin Test Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 40: Europe Fecal Calprotectin Test Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 41: Europe Fecal Calprotectin Test Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 42: Europe Fecal Calprotectin Test Market Value Share Analysis, by Patient Type, 2022 and 2031
  • Figure 43: Europe Fecal Calprotectin Test Market Attractiveness Analysis, by Patient Type, 2023-2031
  • Figure 44: Europe Fecal Calprotectin Test Market Value Share Analysis, by Assay Type, 2022 and 2031
  • Figure 45: Europe Fecal Calprotectin Test Market Attractiveness Analysis, by Assay Type, 2023-2031
  • Figure 46: Europe Fecal Calprotectin Test Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 47: Europe Fecal Calprotectin Test Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 48: Europe Fecal Calprotectin Test Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 49: Europe Fecal Calprotectin Test Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 50: Asia Pacific Fecal Calprotectin Test Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 51: Asia Pacific Fecal Calprotectin Test Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 52: Asia Pacific Fecal Calprotectin Test Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 53: Asia Pacific Fecal Calprotectin Test Market Value Share Analysis, by Patient Type, 2022 and 2031
  • Figure 54: Asia Pacific Fecal Calprotectin Test Market Attractiveness Analysis, by Patient Type, 2023-2031
  • Figure 55: Asia Pacific Fecal Calprotectin Test Market Value Share Analysis, by Assay Type, 2022 and 2031
  • Figure 56: Asia Pacific Fecal Calprotectin Test Market Attractiveness Analysis, by Assay Type, 2023-2031
  • Figure 57: Asia Pacific Fecal Calprotectin Test Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 58: Asia Pacific Fecal Calprotectin Test Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 51: Asia Pacific Fecal Calprotectin Test Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 60: Asia Pacific Fecal Calprotectin Test Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 61: Latin America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 62: Latin America Fecal Calprotectin Test Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 63: Latin America Fecal Calprotectin Test Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 64: Latin America Fecal Calprotectin Test Market Value Share Analysis, by Patient Type, 2022 and 2031
  • Figure 65: Latin America Fecal Calprotectin Test Market Attractiveness Analysis, by Patient Type, 2023-2031
  • Figure 66: Latin America Fecal Calprotectin Test Market Value Share Analysis, by Assay Type, 2022 and 2031
  • Figure 67: Latin America Fecal Calprotectin Test Market Attractiveness Analysis, by Assay Type, 2023-2031
  • Figure 68: Latin America Fecal Calprotectin Test Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 69: Latin America Fecal Calprotectin Test Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 70: Latin America Fecal Calprotectin Test Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 71: Latin America Fecal Calprotectin Test Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 72: Middle East & Africa Fecal Calprotectin Test Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 73: Middle East & Africa Fecal Calprotectin Test Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 74: Middle East & Africa Fecal Calprotectin Test Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 75: Middle East & Africa Fecal Calprotectin Test Market Value Share Analysis, by Patient Type, 2022 and 2031
  • Figure 76: Middle East & Africa Fecal Calprotectin Test Market Attractiveness Analysis, by Patient Type, 2023-2031
  • Figure 77: Middle East & Africa Fecal Calprotectin Test Market Value Share Analysis, by Assay Type, 2022 and 2031
  • Figure 78: Middle East & Africa Fecal Calprotectin Test Market Attractiveness Analysis, by Assay Type, 2023-2031
  • Figure 79: Middle East & Africa Fecal Calprotectin Test Market Value Share Analysis, by Indication, 2022 and 2031
  • Figure 80: Middle East & Africa Fecal Calprotectin Test Market Attractiveness Analysis, by Indication, 2023-2031
  • Figure 81: Middle East & Africa Fecal Calprotectin Test Market Value Share Analysis, by End-user, 2022 and 2031
  • Figure 82: Middle East & Africa Fecal Calprotectin Test Market Attractiveness Analysis, by End-user, 2023-2031
  • Figure 83: Global Fecal Calprotectin Test Market Share, by Company, 2022